The Scientific Associate, iPSC Engineering will utilize their experience and knowledge to design, execute research and development activities focused on engineered cell therapy technologies, with a focus on engineered immune cells. Key responsibilities include, but are not limited to: serving as a subject matter contributor and lab support for the growth, maintenance and optimization of iPSC (induced pluripotent stem cells) cultures and their differentiation into various immunological lineage cells; execution of strategies to optimize iPSC growth characteristics and their differentiation into various immunological cells with a focus toward manufacturing; and interacting with research and CMC teams focused on engineered cell therapy platform development.
Responsibilities: • Research and development on iPSC platform development and optimization • Support the development of therapies focused on engineered immune cells • Identify original, nascent solutions to address key scientific challenges required for platform success • Maintenance of laboratory notebooks for proper documentation of all research activities • Deliver reports, summaries, and presentations supporting experimental results
Qualifications: • Extensive experience with mammalian cell culture at small and large scales • Exposure to cutting-edge cell engineering techniques • Ability to independently propose, design, execute and report research projects • Outstanding collaborative and communication skills
Requirements: • Degree in biology, chemistry or related field with +3 years of experience mammalian cell culture in an industrial setting. • Functional experience in molecular and cellular biology and assay development • Working knowledge of protein biochemistry and basic gene-editing technologies • Understanding of basic flow cytometry or cell imaging technologies
About Century Therapeutics, LLC:
Century Therapeutics is developing novel allogeneic living cell products for oncology that overcome the limitations of first-generation cell therapies. Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophages) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care. https://www.centurytx.com/